Bliss GVS Pharma posts Q1 FY26 PAT higher at Rs. 43.03 Cr
News

Bliss GVS Pharma posts Q1 FY26 PAT higher at Rs. 43.03 Cr

Bliss GVS Pharma has reported total income of Rs. 242.92 crores during the period ended June 30, 2025

  • By IPP Bureau | August 01, 2025

Bliss GVS Pharma Limited has reported Consolidated financial results for the period ended June 30, 2025.

Bliss GVS Pharma has posted net profit of Rs. 43.03 crores for the period ended June 30, 2025 as against net profit of Rs. 15.53 crores for the period ended March 31, 2025. The company posted net profit of Rs.20.69 crores for the period ended June 30, 2024.

Bliss GVS Pharma has reported total income of Rs. 242.92 crores during the period ended June 30, 2025 as compared to Rs. 210.05 crores during the period ended March 31, 2025. The company reported total income of Rs. 187.7654 crores during the period ended June 30, 2024.

Other Related stories

Startup

Digitization

India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
Sanjay Vyas President and Managing Director, Parexel India And Global SBU Head- Safety services & Logistics, Parexel International